查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1718043

生物醫學市場人工智慧的組件、技術、業務功能、應用、最終用戶和部署模式—2025-2030 年全球預測

Artificial Intelligence in Biomedical Market by Component, Technology, Business Function, Application, End User, Deployment Mode - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計生物醫學人工智慧市場規模到 2024 年將達到 28.7 億美元，到 2025 年將達到 32.6 億美元，年複合成長率為 14.65%，到 2030 年將達到 65.3 億美元。

主要市場統計數據
基準年2024年 28.7億美元
預計2025年 32.6億美元
預測年份 2030 65.3億美元
複合年成長率（%） 14.65%

人工智慧的快速發展不僅僅是技術的進步；它代表了生物醫學領域的模式轉移。在過去的十年中，機器學習、數據分析和計算生物學的突破性進展重新定義了研究的進行方式、診斷的開展方式以及患者照護方式。這種轉變由多學科專業知識和不斷成長的生物醫學數據的整合所推動，使人工智慧成為加速創新的重要工具。

在這個不斷變化的情況下，專家和決策者不斷面臨挑戰，需要確定將資源投入到哪裡才能發揮最大作用。這是一個科技與醫療保健之間合作日益加強的故事，先進的演算法與傳統的生物醫學方法攜手並進。因此，這些學科的融合不僅會提高業務效率，還會為個人化醫療和預測分析鋪平道路。

以下部分全面概述了推動人工智慧與生物醫學應用交叉、細分洞察、區域動態和公司策略的關鍵轉變。每個部分都經過仔細研究，呈現出快速變化的行業的整體情況，在這個行業中，利用數位轉型的力量正在推動臨床實踐和研究的突破。

改變潮流：重新定義生物醫學人工智慧

近年來，生物醫藥產業經歷了變革性的變化，重新定義了研究和治療方法。先進演算法模型和計算能力的湧入使得診斷和藥物開發的預測能夠更快、更準確。這種轉變是由技術平台和調查方法的深度融合所推動的，數位工具使曾經只需要人類專業知識就能完成的任務標準化。

這種轉變的主要驅動力是機器學習技術的成熟，當與大型資料集結合時，機器學習技術大大減少了臨床決策流程所需的時間。增強的數據視覺化和高級分析使相關人員能夠識別以前無法察覺的細微趨勢。這些發展將促進從被動醫療轉向主動介入策略的轉變，最終改善患者的治療效果。

此外，雲端處理、邊緣設備和互聯系統的整合為生物醫學創新的新時代奠定了基礎，實現了安全的數據共用和更全面的病患監測方法。隨著自然語言處理和機器人流程自動化等技術的成熟，它們提供了可擴展的解決方案，將常規業務轉變為智慧、自我最佳化的生態系統。這項突破不僅僅是漸進式的改進，而是對生物醫學研究方式和醫療保健方式的全面重新思考。

關鍵細分洞察 深入探究市場方面

細分洞察提供了一個廣泛的框架，有助於理解生物醫學人工智慧市場的不同方面。基於組件的分析強調硬體、服務和軟體的分類，其中硬體進一步分解為記憶體、網路設備和處理器。對服務業的分析著重於諮詢、實施、整合和維護，而對軟體業的分析則涵蓋應用程式、中介軟體和平台。這些層次突顯了技術整合和營運支援的多面性。

如果我們根據技術研究市場，該領域可細分為電腦視覺、機器學習、自然語言處理和機器人流程自動化。電腦視覺本身是透過臉部辨識臉辨識、影像識別和模式辨識等功能進行研究的。機器學習進一步分為深度學習、強化學習、監督學習和無監督學習，以確保捕捉到每個分析細微差別。除此之外，自然語言處理還涉及聊天機器人、語言翻譯、語音辨識和文字分析，而機器人流程自動化則分為有人值守自動化和無人值守自動化。

基於業務功能的細分透過專注於客戶服務、財務和營運來揭示複雜性。客戶服務涉及客戶回饋分析和個人化支持，財務專注於詐欺偵測和風險管理，營運包括流程最佳化和資源分配。臨床試驗著重於數據分析和招募、病理學和放射學診斷、遠端監測方法和穿戴式設備的病患監測以及藥物發現和精準醫療的治療。

進一步基於最終用戶的分析確定了學術和研究機構、政府機構、醫療保健提供者、製藥公司等細分市場。這些細分市場進一步細分為研究中心和大學、公共衛生組織和監管機構、診所和醫院以及生物技術和醫療技術公司。雲端基礎的模型分為混合雲端、私有雲端和公共雲端框架。綜合起來，這些細分為相關人員提供了複雜的藍圖，以便更好地制定生物醫學人工智慧市場的策略。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 對改進診斷工具和改善患者治療結果的需求日益增加
      • 個人化醫療需求的不斷成長將推動人工智慧在生物醫學實踐中的應用
      • 醫療保健數據激增
    • 限制因素
      • 目前人工智慧演算法在準確理解複雜生物系統方面的局限性
    • 機會
      • 應用自然語言處理來增強臨床決策和數據分析
      • 利用人工智慧驅動的運算模型和模擬增強研發
    • 任務
      • 管理生物醫學人工智慧應用中的數據偏差和準確性問題
  • 市場區隔分析
    • 技術：人工智慧技術對生物醫學創新和商業策略的變革性影響
    • 應用：由於診斷準確性和速度的提高，人工智慧應用將在病理學和放射學領域蓬勃發展
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 生物醫藥市場中的人工智慧（按組成部分）

  • 硬體
    • 記憶
    • 網路裝置
    • 處理器
  • 服務
    • 諮詢
    • 執行
    • 一體化
    • 維護
  • 軟體
    • 應用
    • 中介軟體
    • 平台

第7章 生物醫藥市場中的人工智慧（按技術）

  • 電腦視覺
    • 臉部辨識
    • 影像識別
    • 模式識別
  • 機器學習
    • 深度學習
    • 強化學習
    • 監督學習
    • 無監督學習
  • 自然語言處理
    • 聊天機器人
    • 語言翻譯
    • 語音辨識
    • 文字分析
  • 機器人流程自動化
    • 有人值守自動化
    • 無人自動化

第8章生物醫藥市場中的人工智慧（業務功能）

  • 客戶服務
    • 客戶回饋分析
    • 個人化支援
  • 金融
    • 詐欺偵測
    • 風險管理
  • 手術
    • 流程最佳化
    • 資源分配

第9章 生物醫藥市場中的人工智慧應用

  • 臨床試驗
    • 數據分析
    • 招募
  • 診斷
    • 病理
    • 放射學
  • 病患監測
    • 遠端監控
    • 穿戴式裝置
  • 治療
    • 藥物研發
    • 精準醫療

第 10 章。生物醫藥市場中的人工智慧（按最終用戶）

  • 學術研究所
    • 研究中心
    • 大學
  • 政府
    • 公共衛生機構
    • 監管機構
  • 醫療保健提供者
    • 診所
    • 醫院
  • 製藥公司
    • 生技公司
    • 醫療技術公司

第 11 章。按部署模式分類的生物醫藥市場中的人工智慧

  • 雲端基礎
    • 混合雲端
    • 私有雲端
    • 公共雲端
  • 本地

12. 美國生物醫藥人工智慧市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

13. 亞太地區生物醫藥人工智慧市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

14. 歐洲、中東和非洲生物醫藥市場人工智慧

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • AiCure, LLC
  • Arterys Inc.
  • Aspen Technology Inc
  • Atomwise Inc
  • Augmedix, Inc.
  • Behold.ai Technologies Limited
  • BenevolentAI SA
  • BioSymetrics Inc.
  • BPGbio Inc.
  • Butterfly Network, Inc.
  • Caption Health, Inc. by GE Healthcare
  • Cloud Pharmaceuticals, Inc.
  • CloudMedX Inc.
  • Corti ApS
  • Cyclica Inc by Recursion Pharmaceuticals, Inc.
  • Deargen Inc
  • Deep Genomics Incorporated
  • Euretos BV
  • Exscientia plc
  • Google, LLC by Alphabet, Inc.
  • Insilico Medicine
  • Intel Corporation
  • International Business Machines Corporation
  • InveniAI LLC
  • Isomorphic Labs
  • Novo Nordisk A/S
  • Sanofi SA
  • Turbine Ltd.
  • Viseven Europe OU
  • XtalPi Inc.
Product Code: MRR-A6768A62EDFF

The Artificial Intelligence in Biomedical Market was valued at USD 2.87 billion in 2024 and is projected to grow to USD 3.26 billion in 2025, with a CAGR of 14.65%, reaching USD 6.53 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.87 billion
Estimated Year [2025] USD 3.26 billion
Forecast Year [2030] USD 6.53 billion
CAGR (%) 14.65%

The rapid evolution of artificial intelligence is not merely a technological advancement; it represents a paradigm shift in the biomedical sphere. Over the past decade, breakthroughs in machine learning, data analytics, and computational biology have redefined how research is conducted, diagnostics are made, and patient care is delivered. This transformation is bolstered by an integration of multidisciplinary expertise and an ever-increasing volume of biomedical data, making AI an indispensable tool in accelerating innovation.

In this evolving landscape, professionals and decision-makers are consistently challenged with discerning where to invest resources for maximum impact. The narrative that emerges is one of increased collaboration between technology and healthcare, where advanced algorithms work hand in hand with traditional biomedical methods. As a result, the convergence of these realms is not only enhancing operational efficiency but also paving the way for personalized medicine and predictive analytics.

The following sections provide a comprehensive overview of the key shifts, segmentation insights, regional dynamics, and corporate strategies that drive this intersection of AI and biomedical applications. Each segment has been carefully examined to present a holistic view of a rapidly changing industry, one that harnesses the power of digital transformation to foster breakthroughs in clinical practice and research.

Transformative Shifts in the Landscape: Redefining Biomedical AI

In recent years, the biomedical industry has witnessed transformative shifts that have redefined both research and therapeutic approaches. Advanced algorithmic models and an influx of computational power have enabled faster, more accurate predictions in diagnostics and drug development. This transformation is driven by a profound integration between technology platforms and healthcare methodologies, where digital tools now standardize tasks once considered exclusive to human expertise.

A major driver in this shift has been the maturation of machine learning techniques which, when combined with large datasets, have significantly reduced the time required for clinical decision-making processes. Enhanced data visualization and advanced analytics empower stakeholders to identify subtle trends that were previously undetectable. These developments facilitate a transition from reactive care to proactive intervention strategies, ultimately driving better patient outcomes.

Moreover, this new era of biomedical innovation is supported by the integration of cloud computing, edge devices, and interconnected systems that allow for secure data sharing and a more holistic approach to patient monitoring. As technologies like natural language processing and robotic process automation mature, they offer scalable solutions that transform everyday operations into intelligent, self-optimizing ecosystems. This leap forward is not simply a matter of incremental improvement but a comprehensive rethinking of how biomedical research is executed and how healthcare is delivered.

Key Segmentation Insights: A Deep Dive into Market Dimensions

The segmentation insights provide an extensive framework that helps in understanding the diverse facets of the biomedical AI market. The analysis based on component highlights the division into hardware, services, and software, with hardware further dissected into memory, network devices, and processors. The services component is analyzed with a focus on consulting, implementation, integration, and maintenance, while the software category is examined across applications, middleware, and platforms. These layers underscore the multifaceted nature of technological integration and operational support.

When exploring the market based on technology, the field is segmented into computer vision, machine learning, natural language processing, and robotic process automation. Computer vision itself is studied through functionalities like facial recognition, image recognition, and pattern recognition. Machine learning is further divided into deep learning, reinforcement learning, supervised learning, and unsupervised learning, ensuring that every analytic nuance is captured. In parallel, natural language processing delves into chatbots, language translation, speech recognition, and text analysis, and robotic process automation is categorized by attended automation and unattended automation.

The segmentation based on business function reveals its own intricacies by focusing on customer service, finance, and operations. Customer service involves customer feedback analysis and personalized support, finance centers on fraud detection and risk management, and operations encapsulate process optimization and resource allocation. In addition to these dimensions, the application segmentation categorizes the market into clinical trials, diagnostics, patient monitoring, and therapeutics; with clinical trials covering data analysis and recruitment, diagnostics exploring pathology and radiology, patient monitoring looking at remote monitoring methods and wearable devices, and therapeutics emphasizing drug discovery and precision medicine.

Further analysis based on end user identifies segments such as academic and research institutes, government agencies, healthcare providers, and pharmaceutical companies. These segments are further refined into research centers and universities, public health organizations and regulatory bodies, clinics and hospitals, and biotech versus medtech companies respectively. Finally, the deployment mode segmentation distinguishes between cloud-based and on-premise setups, with cloud-based models diving into hybrid cloud, private cloud, and public cloud frameworks. The totality of these segmentation dimensions provides an intricate roadmap for stakeholders to precisely tailor their strategies in the biomedical AI market.

Based on Component, market is studied across Hardware, Services, and Software. The Hardware is further studied across Memory, Network Devices, and Processors. The Services is further studied across Consulting, Implementation, Integration, and Maintenance. The Software is further studied across Applications, Middleware, and Platforms.

Based on Technology, market is studied across Computer Vision, Machine Learning, Natural Language Processing, and Robotic Process Automation. The Computer Vision is further studied across Facial Recognition, Image Recognition, and Pattern Recognition. The Machine Learning is further studied across Deep Learning, Reinforcement Learning, Supervised Learning, and Unsupervised Learning. The Natural Language Processing is further studied across Chatbots, Language Translation, Speech Recognition, and Text Analysis. The Robotic Process Automation is further studied across Attended Automation and Unattended Automation.

Based on Business Function, market is studied across Customer Service, Finance, and Operations. The Customer Service is further studied across Customer Feedback Analysis and Personalized Support. The Finance is further studied across Fraud Detection and Risk Management. The Operations is further studied across Process Optimization and Resource Allocation.

Based on Application, market is studied across Clinical Trials, Diagnostics, Patient Monitoring, and Therapeutics. The Clinical Trials is further studied across Data Analysis and Recruitment. The Diagnostics is further studied across Pathology and Radiology. The Patient Monitoring is further studied across Remote Monitoring and Wearable Devices. The Therapeutics is further studied across Drug Discovery and Precision Medicine.

Based on End User, market is studied across Academic and Research Institutes, Government Agencies, Healthcare Providers, and Pharmaceutical Companies. The Academic and Research Institutes is further studied across Research Centers and Universities. The Government Agencies is further studied across Public Health Organizations and Regulatory Bodies. The Healthcare Providers is further studied across Clinics and Hospitals. The Pharmaceutical Companies is further studied across Biotech Companies and Medtech Companies.

Based on Deployment Mode, market is studied across Cloud-Based and On-Premise. The Cloud-Based is further studied across Hybrid Cloud, Private Cloud, and Public Cloud.

Key Regional Insights: Dynamics Across Global Markets

Examining regional trends reveals that market dynamics vary significantly across different parts of the world. In the Americas, robust innovation ecosystems and significant investment in health technology research are creating favorable conditions for rapid adoption of AI in biomedical applications. High levels of funding and a well-established digital infrastructure further reinforce this region's leading role.

Europe, Middle East & Africa is characterized by diverse regulatory environments that necessitate careful navigation. While Europe is often at the forefront of stringent regulatory standards and ethical guidelines, the Middle East and Africa are emerging as dynamic spaces where governmental initiatives and investments in public health are catalyzing the spread of smart technologies. This combination of tight governance and innovation-led public projects supports sustainable growth in biomedical AI strategies.

In the Asia-Pacific region, the emphasis is on scaling technologies to meet rising healthcare demands, underpinned by the rapid embrace of digital solutions. The region benefits from a large pool of tech-savvy professionals and cost-effective innovation, making it a hotbed for breakthrough applications in patient monitoring, diagnostics, and therapeutics. Each of these regions presents unique opportunities and challenges that industry players must address to fully leverage the transformative potential of AI in biomedicine.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights: Leaders Pioneering Biomedical AI

A detailed review of key companies in the biomedical AI market provides a vivid picture of the competitive landscape. Leading organizations such as AiCure, LLC; Arterys Inc.; Aspen Technology Inc; Atomwise Inc; and Augmedix, Inc. are driving innovation by merging advanced technology with healthcare objectives. Firms like Behold.ai Technologies Limited, BenevolentAI SA, and BioSymetrics Inc. are forging ahead with state-of-the-art solutions in pattern and image recognition, as well as predictive analytics.

Other pioneering companies including BPGbio Inc., Butterfly Network, Inc., and Caption Health, Inc. by GE Healthcare have made significant contributions towards integrating AI with medical imaging and diagnostic protocols. Cloud Pharmaceuticals, Inc., CloudMedX Inc., and Corti ApS are at the forefront of leveraging cloud-based infrastructures and automated decision-making systems to streamline patient care and data management. Deep Genomics Incorporated, along with Cyclica Inc by Recursion Pharmaceuticals, Inc., further expands the narrative by pushing the boundaries of genomic research and molecular data analysis.

Notably, organizations such as Deargen Inc, Euretos BV, Exscientia plc, and Google, LLC by Alphabet, Inc. underscore the deep-rooted collaboration between tech giants and innovative startups. These synergistic partnerships illustrate how multi-disciplinary expertise is reshaping areas like drug discovery, diagnostic accuracy, and personalized medicine. Additional players like Insilico Medicine, Intel Corporation, International Business Machines Corporation, and InveniAI LLC illustrate the impressive array of corporate investment in the sector. Companies such as Isomorphic Labs, Novo Nordisk A/S, Sanofi SA, Turbine Ltd., Viseven Europe OU, and XtalPi Inc. round out this group of industry leaders consistently pushing the envelope on research and commercial innovations in the biomedical AI arena.

The report delves into recent significant developments in the Artificial Intelligence in Biomedical Market, highlighting leading vendors and their innovative profiles. These include AiCure, LLC, Arterys Inc., Aspen Technology Inc, Atomwise Inc, Augmedix, Inc., Behold.ai Technologies Limited, BenevolentAI SA, BioSymetrics Inc., BPGbio Inc., Butterfly Network, Inc., Caption Health, Inc. by GE Healthcare, Cloud Pharmaceuticals, Inc., CloudMedX Inc., Corti ApS, Cyclica Inc by Recursion Pharmaceuticals, Inc., Deargen Inc, Deep Genomics Incorporated, Euretos BV, Exscientia plc, Google, LLC by Alphabet, Inc., Insilico Medicine, Intel Corporation, International Business Machines Corporation, InveniAI LLC, Isomorphic Labs, Novo Nordisk A/S, Sanofi SA, Turbine Ltd., Viseven Europe OU, and XtalPi Inc.. Actionable Recommendations: Strategic Guidance for Industry Leaders

Leaders operating in the dynamic landscape of biomedical AI must adopt agile strategies and invest in forward-thinking technologies. First, it is essential to continuously update technical infrastructure while emphasizing robust cybersecurity measures to protect sensitive health data. Upgrading to systems that support hybrid cloud configurations can offer a balanced approach, delivering both the scalability of public cloud services and the security of private systems.

Second, fostering partnerships between healthcare providers and technology innovators is pivotal. Industry players should initiate cross-disciplinary collaborations that include academic institutions, government agencies, and leading tech companies. Such partnerships not only expedite the development of breakthrough solutions but also ensure that these innovations are grounded in rigorous scientific methodologies.

Third, companies should allocate dedicated resources towards talent development and retention. Continuous professional training in the areas of machine learning, data analytics, and biomedical research will equip teams with the skills required to keep pace with rapidly evolving technologies. Investment in employee education, along with strategic hires, will bolster the capacity for research and operational efficiency.

Furthermore, organizations must regularly analyze market segmentation trends, adjusting product portfolios to meet diverse customer needs. By deploying comprehensive analyses that consider components such as hardware, services, software, and specific technological applications, companies can pivot swiftly in response to emerging demands. In addition, strategic geographical expansion should be considered, with special attention paid to regions showing high growth potential and favorable regulatory environments. These consolidated recommendations can serve as a roadmap for long-term strategic planning and competitive positioning.

Conclusion: Embracing a Data-Driven Future in Biomedical AI

In summary, the penetration of artificial intelligence into the biomedical arena has profoundly reshaped the way research, diagnostics, and patient care are approached. The landscape is undergoing a significant evolution, driven by technological advancements and a growing emphasis on data-driven decision-making. Detailed market segmentation reinforces how multifaceted the industry is, outlining clear distinctions based on component, technology, business function, application, end user, and deployment mode. At the regional level, variations in economic, regulatory, and demographic conditions underline the need for tailored strategies.

Companies operating in this dynamic environment illustrate a strong commitment to innovation and collaboration. Their ability to continuously integrate advanced technologies with traditional biomedical processes is setting the stage for transformative advancements in precision medicine and patient care. As the market matures, stakeholders must remain proactive in adapting to change and leveraging opportunities presented by emerging technologies.

This evolving narrative of biomedical AI, underpinned by comprehensive market segmentation and supported by a global network of key players, points towards a future where health systems become smarter, more efficient, and highly personalized. The journey ahead is challenging but filled with potential, and now is the time to harness these innovations to drive meaningful progress in healthcare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing need for improved diagnostic tools and patient outcomes advancing
      • 5.1.1.2. Rising demand for personalized medicine boosting AI implementation in biomedical practices
      • 5.1.1.3. Surge in healthcare data generation
    • 5.1.2. Restraints
      • 5.1.2.1. Limitations of current AI algorithms in accurately understanding complex biological systems
    • 5.1.3. Opportunities
      • 5.1.3.1. Applying natural language processing to enhance clinical decision-making and data analysis
      • 5.1.3.2. Enhancing research and development through AI-driven computational models and simulations
    • 5.1.4. Challenges
      • 5.1.4.1. Managing data bias and accuracy concerns in AI applications within biomedicine
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology : Transformative impact of AI technologies on biomedical innovations and commercial strategies
    • 5.2.2. Application : Proliferation of AI applications in both pathology and radiology owing to their diagnostic accuracy and speed
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Artificial Intelligence in Biomedical Market, by Component

  • 6.1. Introduction
  • 6.2. Hardware
    • 6.2.1. Memory
    • 6.2.2. Network Devices
    • 6.2.3. Processors
  • 6.3. Services
    • 6.3.1. Consulting
    • 6.3.2. Implementation
    • 6.3.3. Integration
    • 6.3.4. Maintenance
  • 6.4. Software
    • 6.4.1. Applications
    • 6.4.2. Middleware
    • 6.4.3. Platforms

7. Artificial Intelligence in Biomedical Market, by Technology

  • 7.1. Introduction
  • 7.2. Computer Vision
    • 7.2.1. Facial Recognition
    • 7.2.2. Image Recognition
    • 7.2.3. Pattern Recognition
  • 7.3. Machine Learning
    • 7.3.1. Deep Learning
    • 7.3.2. Reinforcement Learning
    • 7.3.3. Supervised Learning
    • 7.3.4. Unsupervised Learning
  • 7.4. Natural Language Processing
    • 7.4.1. Chatbots
    • 7.4.2. Language Translation
    • 7.4.3. Speech Recognition
    • 7.4.4. Text Analysis
  • 7.5. Robotic Process Automation
    • 7.5.1. Attended Automation
    • 7.5.2. Unattended Automation

8. Artificial Intelligence in Biomedical Market, by Business Function

  • 8.1. Introduction
  • 8.2. Customer Service
    • 8.2.1. Customer Feedback Analysis
    • 8.2.2. Personalized Support
  • 8.3. Finance
    • 8.3.1. Fraud Detection
    • 8.3.2. Risk Management
  • 8.4. Operations
    • 8.4.1. Process Optimization
    • 8.4.2. Resource Allocation

9. Artificial Intelligence in Biomedical Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Trials
    • 9.2.1. Data Analysis
    • 9.2.2. Recruitment
  • 9.3. Diagnostics
    • 9.3.1. Pathology
    • 9.3.2. Radiology
  • 9.4. Patient Monitoring
    • 9.4.1. Remote Monitoring
    • 9.4.2. Wearable Devices
  • 9.5. Therapeutics
    • 9.5.1. Drug Discovery
    • 9.5.2. Precision Medicine

10. Artificial Intelligence in Biomedical Market, by End User

  • 10.1. Introduction
  • 10.2. Academic and Research Institutes
    • 10.2.1. Research Centers
    • 10.2.2. Universities
  • 10.3. Government Agencies
    • 10.3.1. Public Health Organizations
    • 10.3.2. Regulatory Bodies
  • 10.4. Healthcare Providers
    • 10.4.1. Clinics
    • 10.4.2. Hospitals
  • 10.5. Pharmaceutical Companies
    • 10.5.1. Biotech Companies
    • 10.5.2. Medtech Companies

11. Artificial Intelligence in Biomedical Market, by Deployment Mode

  • 11.1. Introduction
  • 11.2. Cloud-Based
    • 11.2.1. Hybrid Cloud
    • 11.2.2. Private Cloud
    • 11.2.3. Public Cloud
  • 11.3. On-Premise

12. Americas Artificial Intelligence in Biomedical Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Artificial Intelligence in Biomedical Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Artificial Intelligence in Biomedical Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Strategic agreement between Recursion and Exscientia to enhance AI-driven drug discovery process
    • 15.3.2. Insilico Medicine and NVIDIA launch nach0 transformer to enhance AI-driven biomedical discoveries
    • 15.3.3. HCA Healthcare's adoption of AI-powered Augmedix Go transforms emergency department documentation
    • 15.3.4. Bionl.AI Launches Innovative Platform for No-Code Biomedical Research
    • 15.3.5. Epistemic AI launches biomedical GPT at BIO
    • 15.3.6. NIH launches Bridge2AI program to expand the use of artificial intelligence in biomedical and behavioral research
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AiCure, LLC
  • 2. Arterys Inc.
  • 3. Aspen Technology Inc
  • 4. Atomwise Inc
  • 5. Augmedix, Inc.
  • 6. Behold.ai Technologies Limited
  • 7. BenevolentAI SA
  • 8. BioSymetrics Inc.
  • 9. BPGbio Inc.
  • 10. Butterfly Network, Inc.
  • 11. Caption Health, Inc. by GE Healthcare
  • 12. Cloud Pharmaceuticals, Inc.
  • 13. CloudMedX Inc.
  • 14. Corti ApS
  • 15. Cyclica Inc by Recursion Pharmaceuticals, Inc.
  • 16. Deargen Inc
  • 17. Deep Genomics Incorporated
  • 18. Euretos BV
  • 19. Exscientia plc
  • 20. Google, LLC by Alphabet, Inc.
  • 21. Insilico Medicine
  • 22. Intel Corporation
  • 23. International Business Machines Corporation
  • 24. InveniAI LLC
  • 25. Isomorphic Labs
  • 26. Novo Nordisk A/S
  • 27. Sanofi SA
  • 28. Turbine Ltd.
  • 29. Viseven Europe OU
  • 30. XtalPi Inc.

LIST OF FIGURES

  • FIGURE 1. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET MULTI-CURRENCY
  • FIGURE 2. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET MULTI-LANGUAGE
  • FIGURE 3. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET RESEARCH PROCESS
  • FIGURE 4. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET DYNAMICS
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MEMORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NETWORK DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PROCESSORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CONSULTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY IMPLEMENTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY INTEGRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MIDDLEWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FACIAL RECOGNITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY IMAGE RECOGNITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATTERN RECOGNITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY REINFORCEMENT LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SUPERVISED LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY UNSUPERVISED LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CHATBOTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY LANGUAGE TRANSLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SPEECH RECOGNITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TEXT ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ATTENDED AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY UNATTENDED AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER FEEDBACK ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PERSONALIZED SUPPORT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FRAUD DETECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY RISK MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PROCESS OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY RESOURCE ALLOCATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY RECRUITMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY RADIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY REMOTE MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PRECISION MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY REGULATORY BODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MEDTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 100. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 101. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 102. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 103. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 104. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 106. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 107. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 108. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 109. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 110. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 111. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 112. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 113. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 115. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 116. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 117. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 118. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 120. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 121. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 122. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 123. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 124. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 125. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 126. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 127. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 128. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 129. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 130. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 132. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 133. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 134. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 135. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 136. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 137. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 138. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 141. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 142. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 143. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 144. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 146. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 147. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 148. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 149. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 150. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 151. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 152. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 153. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 154. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 155. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 157. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 158. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 159. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 160. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 161. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 162. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 163. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 164. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 166. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 167. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 168. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 169. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 171. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 172. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 173. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 174. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 175. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 176. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 177. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 178. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 179. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 180. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 182. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 183. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 184. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 185. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 186. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 187. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 188. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 189. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 191. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 192. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 193. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 194. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 196. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 197. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 198. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 199. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 200. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 201. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 202. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 203. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 204. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 205. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 207. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 208. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 209. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 210. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 211. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 212. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 213. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 214. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 216. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 217. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 218. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 219. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 221. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 222. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 223. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 224. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 225. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 243. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 244. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 246. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 247. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 248. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 249. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 250. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 251. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 278. AUSTRALIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 279. AUSTRALIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 280. AUSTRALIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 281. AUSTRALIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 282. AUSTRALIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 283. AUSTRA